Holen Sie sich die Stockscreener-App
4.07
12.74%
0.46
Vorhandelsmarkt:
4.07
Schlusskurs vom Vortag:
$3.61
Offen:
$3.67
24-Stunden-Volumen:
160.24K
Relative Volume:
0.94
Marktkapitalisierung:
$191.82M
Einnahmen:
$103.40K
Nettoeinkommen (Verlust:
$-29.96M
KGV:
-6.312
EPS:
-0.6448
Netto-Cashflow:
$-27.58M
1W Leistung:
+3.30%
1M Leistung:
+28.80%
6M Leistung:
+101.49%
1J Leistung:
+148.17%
1-Tages-Spanne:
$3.67
$4.18
1-Wochen-Bereich:
$3.44
$4.18
52-Wochen-Spanne:
$1.30
$4.5791
Adagene Inc Adr Stock (ADAG) Company Profile
Compare ADAG vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADAG
Adagene Inc Adr
|
4.07 | 191.82M | 103.40K | -29.96M | -27.58M | -0.6448 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Adagene Inc Adr Stock (ADAG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-24 | Eingeleitet | Guggenheim | Buy |
| 2025-08-06 | Eingeleitet | Leerink Partners | Outperform |
| 2025-01-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-25 | Eingeleitet | China Renaissance | Buy |
| 2021-03-08 | Eingeleitet | Goldman | Buy |
| 2021-03-08 | Eingeleitet | Jefferies | Buy |
| 2021-03-08 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Adagene Inc Adr Aktie (ADAG) Neueste Nachrichten
ETFs Investing in Adagene, Inc. Sponsored ADR Stocks - TradingView
AirBoss of America (OTCMKTS:ABSSF) Stock Price Crosses Above 200 Day Moving Average – Here’s What Happened - Defense World
Vaso (OTCMKTS:VASO) Stock Price Passes Above 200 Day Moving Average – Should You Sell? - Defense World
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Adagene (NASDAQ:ADAG) Raised to Hold at Wall Street Zen - MarketBeat
Adagene’s Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA - wahanariau.com
Adagene Inc. (NASDAQ: ADAG) insider reports 2.39M shares, 5.1% stake - Stock Titan
Adagene (NASDAQ: ADAG) CSO reports options and warrant stakes - Stock Titan
Adagene (ADAG) CFO Tam Man Kin details shares, RSUs and options - Stock Titan
Adagene Inc. (ADAG) CEO Peter Luo reports options, RSUs and shares in Form 3 - Stock Titan
Adagene (ADAG) HR executive Form 3 details options, RSUs and shares - Stock Titan
Adagene (NASDAQ: ADAG) director details stock option holdings - Stock Titan
Adagene (ADAG) finance leader lists options, RSUs and shares - Stock Titan
Adagene (NASDAQ: ADAG) director details 70,000-share option position in Form 3 - Stock Titan
Adagene (NASDAQ: ADAG) CMO discloses stock options, RSUs and shares - Stock Titan
Adagene Inc. (ADAG) director lists time and performance stock options - Stock Titan
Adagene's Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA - Bitget
Experimental cancer antibody muzastotug in colon and liver trials at AACR 2026 - Stock Titan
Adagene Inc. (ADAG) director discloses 25,000 shares and 65,000 options - Stock Titan
Ulf Grawunder Net Worth (2026) - GuruFocus
Adagene (ADAG) to Release Earnings on Monday - MarketBeat
Adagene Spotlights ADG126 at Leerink, Teases New MSS Colorectal Cancer Data Update Soon - MarketBeat
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Short Interest Down 24.5% in February - MarketBeat
Adagene Spotlights ADG126+KEYTRUDA Data, Late-Line MSS-CRC Focus in Oppenheimer Conference Talk - MarketBeat
Comparing KALA BIO (NASDAQ:KALA) and Adagene (NASDAQ:ADAG) - Defense World
Adagene to Participate in Two Upcoming Investor Conferences - The Manila Times
Adagene sets Oppenheimer, Leerink fireside chats for Feb. 25, March 9 - Stock Titan
Moderna's Shares Climb 5.3% as Investors Revisit Biotech Leaders - TradingView
Short Interest in Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Rises By 283.2% - Defense World
Short Interest in Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Expands By 283.2% - MarketBeat
Short Interest in Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Drops By 31.1% - MarketBeat
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Maze Therapeutics, Inc. (MAZE), Adagene (ADAG) and Johnson & Johnson (JNJ) - The Globe and Mail
Adagene Provides Business Update and 2026 Objectives - The Manila Times
Short Interest in Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Rises By 48.9% - MarketBeat
Total debt per share of Adagene, Inc. Sponsored ADR – LS:A2QN45 - TradingView — Track All Markets
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Short Interest in Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Declines By 36.8% - MarketBeat
Analysts Set Expectations for Adagene FY2025 Earnings - Defense World
Analysts Issue Forecasts for Adagene FY2025 Earnings - MarketBeat
FDA Grants Fast Track Designation to ADAG's Colorectal Cancer Drug - The Globe and Mail
Adagene, Palvella up after FDA Fast Track tags (ADAG:NASDAQ) - Seeking Alpha
Adagene stock soars after FDA grants Fast Track status for cancer therapy - Investing.com Nigeria
Adagene stock soars after FDA grants Fast Track status for cancer therapy By Investing.com - Investing.com South Africa
FDA grants fast track status to Adagene’s muzastotug for colorectal cancer - Investing.com
FDA grants fast track status to Adagene’s muzastotug for colorectal cancer By Investing.com - Investing.com South Africa
Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126) - GlobeNewswire
Finanzdaten der Adagene Inc Adr-Aktie (ADAG)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):